Skip to main content
SpringerLink
Log in

Markernegatives Nichtseminom CS IIA: Therapie

  • Living reference work entry
  • First Online:
Uroonkologie

Part of the book series: Springer Reference Medizin ((SRM))

  • 112 Accesses

Zusammenfassung

Im klinischen Stadium IIA des nichtseminomatösen Hodentumors muss streng zwischen Patienten unterschieden werden, die die typischen Hodentumormarker persistierend oder ansteigend präsentieren und solchen, die nur eine isolierte bildgebende Raumforderung ≤2 cm im transversalen CT-Durchmesser aufweisen und keine Markerexpression aufweisen. Die markerpositiven Tumore werden als klassische Metastasen stadiengerecht chemotherapiert (3 oder 4 Zyklen BEP), bei markerenegativen Patienten muss die Histologie vor Therapie gesichert werden (CT-Punktion oder RLA).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Literatur

  • Albers P, Albers J, Cummings OW, Boris M, Donohue JP, Foster RS (1995) Flow cytometric and cytophotometric DNA analysis cannot predict subsequent tumour recurrence in pathological stage IIA/B non-seminomatous testicular germ cell tumour patients who do not receive adjuvant chemotherapy [letter]. Eur J Cancer 31A(5):848–849

    Article  CAS  Google Scholar 

  • Beck SD, Cheng L, Bihrle R, Donohue JP, Foster RS (2007) Does the presence of extranodal extension in pathological stage B1 nonseminomatous germ cell tumor necessitate adjuvante chemotherapy? J Urol 177:944–946

    Article  Google Scholar 

  • De Wit M, Hartmann M, Kotzerke J, Wirth M, Brenner W, Hellwig D, Lehmann J, Heicappell R, Bokemeyer C, Bares R (2005) German Multicenter PET Study Group 18F-FDG-PET in clinical stage I and II non-seminomatous germ cell tumors: first results of the German multicenter trial. J Clin Oncol 23:4504 (Supplement)

    Google Scholar 

  • Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R (1995) Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965–1989) using routine primary retroperitoneal lymph node dissection. Eur J Cancer 31A(10):1599–1604

    Article  CAS  Google Scholar 

  • Hartlapp JH, Weissbach L, Bussar-Maatz R (1987) Adjuvant chemotherapy in nonseminomatous testicular tumour stage II. Int J Androl 10(1):277–284

    Article  CAS  Google Scholar 

  • Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10–30

    Article  Google Scholar 

  • Kondagunta GV, Sheinfeld J, Mazumdar M, Mariani TV, Bajorin D, Bacik J, Bosl GJ, Motzer RJ (2004) Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol 22:464–467

    Article  CAS  Google Scholar 

  • Richie JP, Kantoff PW (1991) Is adjuvant chemotherapy necessary for patients with stage B1 testicular cancer? J Clin Oncol 9(8):1393–1396

    Article  CAS  Google Scholar 

  • Sesterhenn IA, Weiss RB, Mostofi FK et al (1992) Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: a report from the Testicular Cancer Intergroup Study. J Clin Oncol 10(1):69–78

    Article  CAS  Google Scholar 

  • Sheinfeld J, Motzer RJ, Rabbani F, McKiernan J, Bajorin D, Bosl GJ (2003) Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and II A nonseminomatous germ cell tumors. J Urol 170:1159–1162

    Article  Google Scholar 

  • Sonneveld DJ, Hoekstra HJ, Van Der Graaf WT, Sluiter WJ, Schraffordt Koops H, Sleijfer DT (1999) The changing distribution of stage in nonseminomatous testicular germ cell tumours, from 1977 to 1996. BJU Int 84:68–74

    Article  CAS  Google Scholar 

  • Steiner H, Peschel R, Janetschek G, Holtl L, Berger AP, Bartsch G, Hobisch A (2004) Long-term results of laparoscopic retroperitoneal lymph node dissection: a single-center 10-year experience. Urology 63:550–555

    Article  Google Scholar 

  • Steiner H, Muller T, Gozzi C, Akkad T, Bartsch G, Berger AP (2006) Related Articles, Links. Two cycles of cisplatin-based chemotherapy for low-volume retroperitoneal stage II nonseminomatous germ cell tumours. BJU Int 98(2):349–352 (Epub 2006 Apr 18)

    Article  CAS  Google Scholar 

  • Stephenson AJ, Bosl GJ, Motzer RJ, Kattan MW, Stasi J, Bajorin DF, Sheinfeld J (2005) Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol 23:2781–2788

    Article  Google Scholar 

  • Weissbach L, Hartlapp JH (1991) Adjuvant chemotherapy of metastatic stage II nonseminomatous testis tumor. J Urol 146(5):1295–1298

    Article  CAS  Google Scholar 

  • Weissbach L, Bussar-Maatz R, Flechtner H, Pichlmeier U, Hartmann M, Keller L (2000) RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. Eur Urol 37(5):582–594

    Article  CAS  Google Scholar 

  • Williams SD, Stablein DM, Einhorn LH et al (1987) Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 317(23):1433–1438

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Urologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Deutschland

    Peter Albers

Authors
  1. Peter Albers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Albers .

Editor information

Editors and Affiliations

  1. Helios Marien Klinikum Duisburg, Duisburg, Nordrhein-Westfalen, Germany

    Herbert Rübben

  2. Urologische Klinik/Poliklinik, Universitätsklinikum Rostock, Rostock, Mecklenburg-Vorpommern, Germany

    Oliver Hakenberg

  3. Klinik und Poliklinik für Urologie , Universitätsklinikum Jena, Jena, Thüringen, Germany

    Marc-Oliver Grimm

  4. Caritaskrankenhaus St. Josef, Regensburg, Germany

    Maximilian Burger

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Albers, P. (2019). Markernegatives Nichtseminom CS IIA: Therapie. In: Rübben, H., Hakenberg, O., Grimm, MO., Burger, M. (eds) Uroonkologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-54652-9_68-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-54652-9_68-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-54652-9

  • Online ISBN: 978-3-662-54652-9

  • eBook Packages: Springer Referenz Medizin

Publish with us

Policies and ethics

Search

Navigation